Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.57 USD | +3.75% | +13.73% | +30.67% |
Mar. 25 | Aerovate Therapeutics Q4 Loss Widens | MT |
Mar. 25 | Aerovate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 794M |
---|---|---|---|---|---|
Net income 2024 * | -90M | Net income 2025 * | -97M | EV / Sales 2024 * | - |
Net cash position 2024 * | 63.08M | Net Debt 2025 * | 6.79M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-9.31
x | P/E ratio 2025 * |
-9.43
x | Employees | 51 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.27% |
1 day | +13.14% | ||
1 week | +12.09% | ||
Current month | +25.74% | ||
1 month | +22.09% | ||
3 months | +19.67% | ||
6 months | +113.07% | ||
Current year | +28.24% |
Managers | Title | Age | Since |
---|---|---|---|
Benjamin Dake
FOU | Founder | 48 | 18-07-26 |
Timothy P. Noyes
CEO | Chief Executive Officer | 62 | 21-01-31 |
George Eldridge
DFI | Director of Finance/CFO | 61 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Donald Santel
BRD | Director/Board Member | 62 | 23-01-18 |
Maha Katabi
BRD | Director/Board Member | 50 | 20-07-31 |
Timothy P. Noyes
CEO | Chief Executive Officer | 62 | 21-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 8 M€ | +9.29% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 29.57 | +3.75% | 216 915 |
24-03-27 | 28.5 | +11.11% | 922,350 |
24-03-26 | 25.65 | -4.82% | 271,347 |
24-03-25 | 26.95 | +4.54% | 224,601 |
24-03-22 | 25.78 | -0.85% | 90,513 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.24% | 794M | |
+9.16% | 45.97B | |
+54.26% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |